ライフサイエンスコーパス: small cell carcinoma

1 adenocarcinoma, squamous cell carcinoma, and small cell carcinoma).

2 found in tumor samples of patients with non-small cell carcinoma.

3 adenocarcinoma, squamous cell carcinoma, and small cell carcinoma.

4 CYP2E1 polymorphisms were also suggested for small cell carcinoma.

5 opy 2 days later and was diagnosed as having small cell carcinoma.

6 antibody binding type V were associated with small cell carcinoma.

7 found, predominantly adenocarcinoma and non-small cell carcinoma.

8 nodes confirmed a poorly differentiated non-small-cell carcinoma.

9 plastic neurological autoimmunity related to small-cell carcinoma.

10 oximately 170 kDa antigen, in cerebellum and small-cell carcinoma.

11 s with advanced ovarian cancer and extensive small-cell carcinoma.

12 d patients with renal cell carcinoma and non-small-cell carcinoma.

13 specificity for central airway squamous and small cell carcinomas.

14 as: large cell neuroendocrine carcinomas and small cell carcinomas.

15 l state and potential therapeutic target for small cell carcinomas.

16 enign typical carcinoids to highly malignant small-cell carcinomas.

17 with aggressive tumor characteristics in non-small-cell carcinomas.

18 ally the tumors in all six patients were non-small-cell carcinomas.

19 Eleven patients had confirmed small-cell carcinoma; 1 had imaging evidence of lung can

20 , followed by squamous cell carcinoma (19%), small cell carcinoma (19%), and others (12%).

21 is described in 16 patients: 11 with limited small-cell carcinoma, 2 with lung cancer revealed by ima

22 17.8-23.0%, other lung cancers = 24.5-35.5%, small-cell carcinoma = 9.7%-11.3%).

23 istinct neuronal nAChR subtypes expressed in small-cell carcinomas account for several lung cancer-re

24 Nine non-small cell carcinomas (adenocarcinoma, n = 4, including

25 In small cell carcinoma all stages should be treated with p

26 ions frequently deleted in lung cancer in 13 small cell carcinoma and 17 non-small cell lung carcinom

27 ated with radiotherapy efficacy in human non-small cell carcinoma and melanoma patients.

28 1.6; CI, 1.1-2.5), but not for subjects with small cell carcinomas and adenocarcinomas.

29 associations were strongest for squamous and small cell carcinomas and weaker for adenocarcinoma.

30 ations and X chromosome inactivation between small-cell carcinoma and coexisting urothelial carcinoma

31 y in 116 CRPC tumors: 78 adenocarcinomas, 11 small cell carcinomas, and 27 anaplastic carcinomas.

32 itute an initial event in the development of small cell carcinomas, and 3) loss of heterozygosity at

33 e pancreas and ectopic peptide production in small-cell carcinoma, and to study PC2-dependent proteol

34 Incidence rates of adenocarcinoma, small-cell carcinoma, and undifferentiated tumours were

35 p130 is mutated in a human cell line of lung small cell carcinoma as well as in primary lung tumors.

36 because preoperative histologic diagnosis of small-cell carcinoma can dramatically alter the manageme

37 as, 7,426 squamous cell carcinoma, and 2,664 small-cell carcinoma cases) and 56,450 controls.

38 Small cell carcinoma cells exhibited divergent expressio

39 pe (adenocarcinoma, squamous cell carcinoma, small cell carcinoma) for levels (tertiles and medians)

40 here were too few cases of squamous cell and small cell carcinoma in never smokers to eliminate the p

41 Cancer was diagnosed in 62% of the patients (small-cell carcinoma in 83%).

42 ted the effects of neddylation inhibition in small cell carcinoma, including the ability of MLN4924 t

43 by additional neural autoantibody markers of small-cell carcinoma, including collapsin response-media

44 t promote primary tumor growth of large- and small-cell carcinoma, it did promote spontaneous metasta

45 ally, although LCNEC is categorized as a non-small-cell carcinoma, it is more akin genetically and im

46 dition, we found ganglionic nAChR protein in small-cell carcinoma lines, identifying this cancer as a

47 l carcinoma cell lines, but not in large- or small-cell carcinoma lines.

48 one of which was initially misdiagnosed as a small-cell carcinoma, manifested a heterogeneous RB-posi

49 4,036), squamous cell carcinoma (n = 1,998), small cell carcinoma (n = 1,524), undifferentiated carci

50 ) and irregular margin (n = 5, 71%); for non-small cell carcinoma not otherwise specified (n = 5), so

51 Tumors previously classified as non-small-cell carcinoma, not otherwise specified, because o

52 arcinoma (SCC) and 135 of 279 (48%) with non-small cell carcinoma (NSCC) had positive aspirates (p =

53 Small cell carcinoma of the bladder (SCCB) is a rare and

54 h as squamous cell carcinoma of the bladder, small cell carcinoma of the bladder, adenocarcinoma of t

55 reported to be autocrine growth factors for small cell carcinoma of the lung (SCCL).

56 us to human chromosome 3p gene(s) deleted in small cell carcinoma of the lung (SCLC).

57 The antibody was first associated with small cell carcinoma of the lung and is most often used

58 Similar to published studies of small cell carcinoma of the lung, collaborative efforts

59 isease treatments has been extrapolated from small cell carcinoma of the lung.

60 arcinoma and squamous cell carcinoma but not small cell carcinoma of the lung.

61 cell tumours, sex cord-stromal tumours, and small cell carcinoma of the ovary of hypercalcaemic type

62 Small cell carcinoma of the ovary of hypercalcemic type

63 SWI/SNF chromatin remodelling gene, underlie small cell carcinoma of the ovary, hypercalcemic type (S

64 Small cell carcinoma of the ovary, hypercalcemic type (S

65 Small cell carcinoma of the ovary, hypercalcemic type (S

66 Small cell carcinoma of the ovary, hypercalcemic type (S

67 f the SMARCA4 and SMARCA2 ATPase subunits in small cell carcinoma of the ovary, hypercalcemic type (S

68 Small cell carcinoma of the ovary, hypercalcemic type (S

69 Small cell carcinoma of the ovary, hypercalcemic type (S

70 Primary small cell carcinoma of the pancreas (SCCP) is a rare ma

71 or understanding the origin and treatment of small cell carcinoma of the urinary bladder has become e

72 Small cell carcinoma of the urinary bladder is a rare an

73 The direction of investigation of small cell carcinoma of the urinary bladder using novel

74 The two small cell carcinomas of the lung showed little or no st

75 ibitors, generally DAF and CD59, whereas non-small cell carcinomas of the lung usually expressed CD59

76 that most carcinomas, with the exception of small cell carcinomas of the lung, do express one or mor

77 Stage is an important prognostic factor in small-cell carcinoma of the cervix, uterus, and ovary.

78 al and pathologic records for three cases of small-cell carcinoma of the esophagus contributed to the

79 chromosome 17p13 (TP53) in 20 patients with small-cell carcinoma of the urinary bladder and concurre

80 In most cases, small-cell carcinoma of the urinary bladder is admixed w

81 RECENT FINDINGS: Small-cell carcinomas of gynecologic sites are rare and

82 o correctly diagnose and treat patients with small-cell carcinomas of the cervix, ovary, uterus, vagi

83 Small-cell carcinomas of the esophagus can have similar

84 PURPOSE OF REVIEW: Small-cell carcinomas of the gynecologic tract are aggre

85 The small-cell carcinomas of the vagina and vulva need to be

86 large-cell neuroendocrine carcinoma, but not small-cell carcinoma or carcinoids.

87 A MEDLINE search was done, using the terms "small cell carcinoma" or "oat cell carcinoma" combined w

88 it was not detected in large cell carcinoma, small cell carcinoma, or atypical lung neuroendocrine ca

89 urther tested in PSMA-negative CRPC, such as small cell carcinoma, other molecular imaging modalities

90 sensitized NE-transformed lung and prostate small cell carcinoma PDXs to standard cytotoxics.

91 all tumor passages exhibit a neuroendocrine/small cell carcinoma phenotype-insensitivity to androgen

92 tumors from intrapulmonary metastases in non-small-cell carcinoma remains a clinical dilemma with sig

93 2589 squamous cell carcinomas (SQ), and 1418 small cell carcinomas (SC).

94 bronchogenic carcinoma, 50 of 81 (62%) with small cell carcinoma (SCC) and 135 of 279 (48%) with non

95 kers of neurological autoimmunity related to small-cell carcinoma, their frequency being ANNA-1 > col

96 with pure squamous cell, adenocarcinoma, or small cell carcinoma, there is clear evidence to alter t

97 (PDX) models of pulmonary and extrapulmonary small cell carcinoma treated ex vivo or in vivo.

98 cancer models in the repository include four small cell carcinomas, two large cell neuroendocrine car

99 to a mixture of tumor phenotypes, including small cell carcinoma, urothelial carcinoma, and squamous

100 Less differentiated tumors, diagnosed as small cell carcinomas, were also observed in two of the

101 g fibroblasts are frequent in human lung non-small cell carcinomas, where they seem to actively promo